A decrease in the number of NEUTROPHILS found in the blood.
Fever accompanied by a significant reduction in the number of NEUTROPHILS.
FEVER accompanied by a significant reduction in NEUTROPHIL count associated with CHEMOTHERAPY.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
An abnormal elevation of body temperature, usually as a result of a pathologic process.
A group of diterpenoid CYCLODECANES named for the taxanes that were discovered in the TAXUS tree. The action on MICROTUBULES has made some of them useful as ANTINEOPLASTIC AGENTS.
Drug therapy given to augment or stimulate some other form of treatment such as surgery or radiation therapy. Adjuvant chemotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.
Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience.
A glycoprotein of MW 25 kDa containing internal disulfide bonds. It induces the survival, proliferation, and differentiation of neutrophilic granulocyte precursor cells and functionally activates mature blood neutrophils. Among the family of colony-stimulating factors, G-CSF is the most potent inducer of terminal differentiation to granulocytes and macrophages of leukemic myeloid cell lines.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS BREVIFOLIA. It stabilizes MICROTUBULES in their polymerized form leading to cell death.
Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it.
Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)
Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.
Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity.
An alkaloid isolated from the stem wood of the Chinese tree, Camptotheca acuminata. This compound selectively inhibits the nuclear enzyme DNA TOPOISOMERASES, TYPE I. Several semisynthetic analogs of camptothecin have demonstrated antitumor activity.
Tumors or cancer of the LUNG.
An organoplatinum compound that possesses antineoplastic activity.
A decrease in the number of GRANULOCYTES; (BASOPHILS; EOSINOPHILS; and NEUTROPHILS).
Tumors or cancer of the human BREAST.
The highest dose of a biologically active agent given during a chronic study that will not reduce longevity from effects other than carcinogenicity. (from Lewis Dictionary of Toxicology, 1st ed)
The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.
A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
Fever in which the etiology cannot be ascertained.
Organic compounds which contain platinum as an integral part of the molecule.
Positional isomer of CYCLOPHOSPHAMIDE which is active as an alkylating agent and an immunosuppressive agent.
A subnormal level of BLOOD PLATELETS.
Disorders of the blood and blood forming tissues.
Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, immunotherapy, hyperthermia, etc.) that precedes a necessary second modality of treatment.
Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.
The relationship between the dose of an administered drug and the response of the organism to the drug.
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.
An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.
Organic compounds that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.
An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.
Antimetabolites that are useful in cancer chemotherapy.
Infections by bacteria, general or unspecified.
A therapeutic approach, involving chemotherapy, radiation therapy, or surgery, after initial regimens have failed to lead to improvement in a patient's condition. Salvage therapy is most often used for neoplastic diseases.
Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.
The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.
Substances that reduce the growth or reproduction of BACTERIA.
An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA.
An infection caused by an organism which becomes pathogenic under certain conditions, e.g., during immunosuppression.
Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.
An INFLAMMATION of the MUCOSA with burning or tingling sensation. It is characterized by atrophy of the squamous EPITHELIUM, vascular damage, inflammatory infiltration, and ulceration. It usually occurs at the mucous lining of the MOUTH, the GASTROINTESTINAL TRACT or the airway due to chemical irritations, CHEMOTHERAPY, or radiation therapy (RADIOTHERAPY).
Use of antibiotics before, during, or after a diagnostic, therapeutic, or surgical procedure to prevent infectious complications.
A human or animal whose immunologic mechanism is deficient because of an immunodeficiency disorder or other disease or as the result of the administration of immunosuppressive drugs or radiation.
The forcible expulsion of the contents of the STOMACH through the MOUTH.
Antagonist of urate oxidase.
Congener of FLUOROURACIL with comparable antineoplastic action. It has been suggested especially for the treatment of breast neoplasms.
A malignant epithelial tumor with a glandular organization.
A building block of penicillin, devoid of significant antibacterial activity. (From Merck Index, 11th ed)
An anthracenedione-derived antineoplastic agent.
The active metabolite of FOLIC ACID. Leucovorin is used principally as an antidote to FOLIC ACID ANTAGONISTS.
Elements of limited time intervals, contributing to particular results or situations.
The giving of drugs, chemicals, or other substances by mouth.
The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.
The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells.
A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026)
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2. It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors.
Inorganic compounds which contain platinum as the central atom.
Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.
Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms.
Studies to determine the advantages or disadvantages, practicability, or capability of accomplishing a projected plan, study, or project.
The presence of viable bacteria circulating in the blood. Fever, chills, tachycardia, and tachypnea are common acute manifestations of bacteremia. The majority of cases are seen in already hospitalized patients, most of whom have underlying diseases or procedures which render their bloodstreams susceptible to invasion.
A nonparametric method of compiling LIFE TABLES or survival tables. It combines calculated probabilities of survival and estimates to allow for observations occurring beyond a measurement threshold, which are assumed to occur randomly. Time intervals are defined as ending each time an event occurs and are therefore unequal. (From Last, A Dictionary of Epidemiology, 1995)
An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA TOPOISOMERASES, TYPE I.
Cyclic hydrocarbons that contain multiple rings and share one or more atoms.
Proteins prepared by recombinant DNA technology.
Absence of hair from areas where it is normally present.
Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab.
An antitumor alkaloid isolated from VINCA ROSEA. (Merck, 11th ed.)
Tumors or cancer of the STOMACH.
Semisynthetic, broad-spectrum, AMPICILLIN derived ureidopenicillin antibiotic proposed for PSEUDOMONAS infections. It is also used in combination with other antibiotics.
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.
Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues.
A broad-spectrum antibiotic derived from KANAMYCIN. It is reno- and oto-toxic like the other aminoglycoside antibiotics.
INFLAMMATION of the soft tissues of the MOUTH, such as MUCOSA; PALATE; GINGIVA; and LIP.
Invasion of the host organism by microorganisms that can cause pathological conditions or diseases.
Initial drug treatment designed to bring about REMISSION INDUCTION. It is typically a short-term and high-dose drug treatment that is followed by CONSOLIDATION CHEMOTHERAPY and then MAINTENANCE CHEMOTHERAPY.
Antibodies obtained from a single clone of cells grown in mice or rats.
The return of a sign, symptom, or disease after a remission.
Derivatives of GLUTAMIC ACID. Included under this heading are a broad variety of acid forms, salts, esters, and amides that contain the 2-aminopentanedioic acid structure.
Transplantation of an individual's own tissue from one site to another site.
Tumors or cancer of the URINARY TRACT in either the male or the female.
Tumors or cancer of the PERITONEUM.
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
A subspecialty of internal medicine concerned with morphology, physiology, and pathology of the blood and blood-forming tissues.
A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.
Works about clinical trials that involve at least one test treatment and one control treatment, concurrent enrollment and follow-up of the test- and control-treated groups, and in which the treatments to be administered are selected by a random process, such as the use of a random-numbers table.
Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.
BIOLOGIC PRODUCTS that are imitations but not exact replicas of innovator products.
Transfer of HEMATOPOIETIC STEM CELLS from BONE MARROW or BLOOD between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). Hematopoietic stem cell transplantation has been used as an alternative to BONE MARROW TRANSPLANTATION in the treatment of a variety of neoplasms.
Health care services provided to patients on an ambulatory basis, rather than by admission to a hospital or other health care facility. The services may be a part of a hospital, augmenting its inpatient services, or may be provided at a free-standing facility.
An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)
A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.
A screening assay for circulating COMPLEMENT PROTEINS. Diluted SERUM samples are added to antibody-coated ERYTHROCYTES and the percentage of cell lysis is measured. The values are expressed by the so called CH50, in HEMOLYTIC COMPLEMENT units per milliliter, which is the dilution of serum required to lyse 50 percent of the erythrocytes in the assay.
An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.
A statistical means of summarizing information from a series of measurements on one individual. It is frequently used in clinical pharmacology where the AUC from serum levels can be interpreted as the total uptake of whatever has been administered. As a plot of the concentration of a drug against time, after a single dose of medicine, producing a standard shape curve, it is a means of comparing the bioavailability of the same drug made by different companies. (From Winslade, Dictionary of Clinical Research, 1992)
Antibodies produced by a single clone of cells.
Institutions specializing in the care of cancer patients.
Beta-lactam antibiotics that differ from PENICILLINS in having the thiazolidine sulfur atom replaced by carbon, the sulfur then becoming the first atom in the side chain. They are unstable chemically, but have a very broad antibacterial spectrum. Thienamycin and its more stable derivatives are proposed for use in combinations with enzyme inhibitors.
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
A general term for various neoplastic diseases of the lymphoid tissue.
A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.
Therapy with two or more separate preparations given for a combined effect.
A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)
Therapeutic act or process that initiates a response to a complete or partial remission level.
Infections caused by bacteria that show up as pink (negative) when treated by the gram-staining method.
Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela.
A generic concept reflecting concern with the modification and enhancement of life attributes, e.g., physical, political, moral and social environment; the overall condition of a human life.
A measure of the quality of health care by assessment of unsuccessful results of management and procedures used in combating disease, in individual cases or series.
A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.
A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.
A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm but is often wrongly used as a synonym for "cancer." (From Dorland, 27th ed)
Small-scale tests of methods and procedures to be used on a larger scale if the pilot study demonstrates that these methods and procedures can work.
An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564)
The period of confinement of a patient to a hospital or other health facility.
Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system.
A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS.
Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)
The qualitative or quantitative estimation of the likelihood of adverse effects that may result from exposure to specified health hazards or from the absence of beneficial influences. (Last, Dictionary of Epidemiology, 1988)
Granular leukocytes having a nucleus with three to five lobes connected by slender threads of chromatin, and cytoplasm containing fine inconspicuous granules and stainable by neutral dyes.
A group of broad-spectrum antibiotics first isolated from the Mediterranean fungus ACREMONIUM. They contain the beta-lactam moiety thia-azabicyclo-octenecarboxylic acid also called 7-aminocephalosporanic acid.
Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture.
Glycoproteins found in a subfraction of normal mammalian plasma and urine. They stimulate the proliferation of bone marrow cells in agar cultures and the formation of colonies of granulocytes and/or macrophages. The factors include INTERLEUKIN-3; (IL-3); GRANULOCYTE COLONY-STIMULATING FACTOR; (G-CSF); MACROPHAGE COLONY-STIMULATING FACTOR; (M-CSF); and GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; (GM-CSF).
Infections caused by bacteria that retain the crystal violet stain (positive) when treated by the gram-staining method.
An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.
Semisynthetic, broad-spectrum antibacterial derived from CEPHALORIDINE and used especially for Pseudomonas and other gram-negative infections in debilitated patients.
Neoplasm drug therapy involving an extracorporeal circuit with temporary exclusion of the tumor-bearing area from the general circulation during which high concentrations of the drug are perfused to the isolated part.
Radiotherapy given to augment some other form of treatment such as surgery or chemotherapy. Adjuvant radiotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.
A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.
A rare complication of rheumatoid arthritis with autoimmune NEUTROPENIA; and SPLENOMEGALY.
An enzyme that catalyzes the hydrolysis of proteins, including elastin. It cleaves preferentially bonds at the carboxyl side of Ala and Val, with greater specificity for Ala. EC 3.4.21.37.
Nucleosides containing arabinose as their sugar moiety.
Injections made into a vein for therapeutic or experimental purposes.
The state of weariness following a period of exertion, mental or physical, characterized by a decreased capacity for work and reduced efficiency to respond to stimuli.
A set of techniques used when variation in several variables has to be studied simultaneously. In statistics, multivariate analysis is interpreted as any analytic method that allows simultaneous study of two or more dependent variables.
Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.
The use of IONIZING RADIATION to treat malignant NEOPLASMS and some benign conditions.
An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.
The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells.
A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment.
Tumors or cancer of the TESTIS. Germ cell tumors (GERMINOMA) of the testis constitute 95% of all testicular neoplasms.
A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
The practice of administering medications in a manner that poses more risk than benefit, particularly where safer alternatives exist.
An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
Tumors or cancer located in bone tissue or specific BONES.
Tumors or cancer of the LIVER.
A cell surface protein-tyrosine kinase receptor that is overexpressed in a variety of ADENOCARCINOMAS. It has extensive homology to and heterodimerizes with the EGF RECEPTOR, the ERBB-3 RECEPTOR, and the ERBB-4 RECEPTOR. Activation of the erbB-2 receptor occurs through heterodimer formation with a ligand-bound erbB receptor family member.
Tumors or cancer of the ESOPHAGUS.
An acidic glycoprotein of MW 23 kDa with internal disulfide bonds. The protein is produced in response to a number of inflammatory mediators by mesenchymal cells present in the hemopoietic environment and at peripheral sites of inflammation. GM-CSF is able to stimulate the production of neutrophilic granulocytes, macrophages, and mixed granulocyte-macrophage colonies from bone marrow cells and can stimulate the formation of eosinophil colonies from fetal liver progenitor cells. GM-CSF can also stimulate some functional activities in mature granulocytes and macrophages.
The number of LEUKOCYTES and ERYTHROCYTES per unit volume in a sample of venous BLOOD. A complete blood count (CBC) also includes measurement of the HEMOGLOBIN; HEMATOCRIT; and ERYTHROCYTE INDICES.
An alkylating agent of value against both hematologic malignancies and solid tumors.
Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection.
The actual costs of providing services related to the delivery of health care, including the costs of procedures, therapies, and medications. It is differentiated from HEALTH EXPENDITURES, which refers to the amount of money paid for the services, and from fees, which refers to the amount charged, regardless of cost.
Receptors that bind and internalize GRANULOCYTE COLONY-STIMULATING FACTOR. Their MW is believed to be 150 kD. These receptors are found mainly on a subset of myelomonocytic cells.
The confinement of a patient in a hospital.
Regional infusion of drugs via an arterial catheter. Often a pump is used to impel the drug through the catheter. Used in therapy of cancer, upper gastrointestinal hemorrhage, infection, and peripheral vascular disease.
In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test.
Studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics.
Care alleviating symptoms without curing the underlying disease. (Stedman, 25th ed)
Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals.
The total amount of radiation absorbed by tissues as a result of radiotherapy.
A method of comparing the cost of a program with its expected benefits in dollars (or other currency). The benefit-to-cost ratio is a measure of total return expected per unit of money spent. This analysis generally excludes consideration of factors that are not measured ultimately in economic terms. Cost effectiveness compares alternative ways to achieve a specific set of results.
Neoplasms composed of primordial GERM CELLS of embryonic GONADS or of elements of the germ layers of the EMBRYO, MAMMALIAN. The concept does not refer to neoplasms located in the gonads or present in an embryo or FETUS.
A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).
A peptide hormone that lowers calcium concentration in the blood. In humans, it is released by thyroid cells and acts to decrease the formation and absorptive activity of osteoclasts. Its role in regulating plasma calcium is much greater in children and in certain diseases than in normal adults.
The use of DRUGS to treat a DISEASE or its symptoms. One example is the use of ANTINEOPLASTIC AGENTS to treat CANCER.
A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS.
Cyclic hexapeptides of proline-ornithine-threonine-proline-threonine-serine. The cyclization with a single non-peptide bond can lead them to be incorrectly called DEPSIPEPTIDES, but the echinocandins lack ester links. Antifungal activity is via inhibition of 1,3-beta-glucan synthase production of BETA-GLUCANS.
Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.
A specific mannose-binding member of the collectin family of lectins. It binds to carbohydrate groups on invading pathogens and plays a key role in the MANNOSE-BINDING LECTIN COMPLEMENT PATHWAY.
Vinblastine derivative with antineoplastic activity against CANCER. Major side effects are myelosuppression and neurotoxicity. Vindesine is used extensively in chemotherapy protocols (ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS).
A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)
Drugs used to prevent NAUSEA or VOMITING.
The transference of BONE MARROW from one human or animal to another for a variety of purposes including HEMATOPOIETIC STEM CELL TRANSPLANTATION or MESENCHYMAL STEM CELL TRANSPLANTATION.
Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time.
Platinum. A heavy, soft, whitish metal, resembling tin, atomic number 78, atomic weight 195.09, symbol Pt. (From Dorland, 28th ed) It is used in manufacturing equipment for laboratory and industrial use. It occurs as a black powder (platinum black) and as a spongy substance (spongy platinum) and may have been known in Pliny's time as "alutiae".
Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.
Levels within a diagnostic group which are established by various measurement criteria applied to the seriousness of a patient's disorder.

Mortality, length of stay, and cost associated with hospitalized adult cancer patients with febrile neutropenia. (1/10)

BACKGROUND: Febrile neutropenia (FN) is a serious complication following chemotherapy and is associated with significant mortality and financial expenditure. The aim of this study was to evaluate risk factors for longer length of stay (LOS) and mortality and cost of treatment among hospitalized adults with cancer who developed febrile neutropenia in Thailand. MATERIALS AND METHODS: Information on illness of inpatients and casualties came from hospitals nationwide and from hospital withdrawals from the 3 health insurance schemes in fiscal 2010. The data covered 96% of the population and were analyzed by age groups, hospital level, and insurance year schemes in patients with febrile neutropenia. RESULTS: A total of 5,809 patients were identified in the study. The mortality rate was 14%. The median LOS was 8.67 days and 69% of patients stayed for longer than 5 days. On bivariate analysis, age, cancer type, and infectious complications (bacteremia/sepsis, hypotension, fungal infections, and pneumonia) were significantly associated with longer LOS and death. On multivariate analysis, acute leukemia and infectious complications were linked with longer LOS and death significantly. The median cost of hospitalized FN was THB 33,686 (USD 1,122) with the highest cost observed in acute leukemia patients. CONCLUSIONS: FN in adult patients results in significant mortality in hospitalized Thai patients. Factors associated with increased mortality include older age (>70), acute leukemia, comorbidity, and infectious complications.  (+info)

Febrile neutropenia in the tropics: a description of clinical and microbiological findings and their impact on inappropriate therapy currently used at an oncological reference center in Colombia. (2/10)

 (+info)

Performance of serum biomarkers for the early detection of invasive aspergillosis in febrile, neutropenic patients: a multi-state model. (3/10)

 (+info)

Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi. (4/10)

 (+info)

Comparison of pegfilgrastim prescribing practice to national guidelines at a university hospital outpatient oncology clinic. (5/10)

 (+info)

Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma. (6/10)

 (+info)

Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). (7/10)

 (+info)

Study design: two long-term observational studies of the biosimilar filgrastim Nivestim (Hospira filgrastim) in the treatment and prevention of chemotherapy-induced neutropenia. (8/10)

 (+info)

Nivestim 12 MU/ 0.2 ml solution for injection/infusion, Nivestim 30 MU/ 0.5 ml solution for injection/infusion, Nivestim 48MU/ 0.5 ml solution for injection/infusion - Summary of Product Characteristics (SmPC) by Hospira UK Ltd
Chemotherapy-Induced Febrile Neutropenia Market. The Chemotherapy Induced Febrile Neutropenia market size is expected to increase during the forecast period owing to the launch of upcoming therapies and the increase in the geriatric population in the 7MM.. The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Chemotherapy-Induced Febrile Neutropenia market size and share by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.. The report gives a thorough detail of the Chemotherapy-Induced Febrile Neutropenia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key ...
TY - JOUR. T1 - Pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in patients with solid tumors. AU - Lambertini, Matteo. AU - Ferreira, Arlindo R.. AU - Del Mastro, Lucia. AU - Danesi, Romano. AU - Pronzato, Paolo. PY - 2015/10/22. Y1 - 2015/10/22. N2 - Introduction: Neutropenia and febrile neutropenia are the most common and most severe bone marrow toxicities of chemotherapy. Recombinant granulocyte-colony stimulating factors (G-CSFs), both daily (filgrastim and biosimilars, and lenograstim) and long-acting (pegfilgrastim and lipegfilgrastim) formulations, are currently available to counteract the negative consequences of these side effects. Areas covered: The purpose of this article is to review the physiopathology of chemotherapy-induced febrile neutropenia and its consequences, and the current evidence regarding the pharmacological properties, clinical efficacy and cost-effectiveness of pegfilgrastim as a strategy to prevent chemotherapy-induced febrile ...
June 02, 2017 / 7:30 am, CEST Planegg/Munich, Germany, June 2, 2017. MorphoSys Starts Phase 3 Trial of MOR208 plus Bendamustine in Patients with Relapsed or Refractory DLBCL. First pivotal study with compound from MorphoSyss proprietary portfolio started, following IDMC recommendation after initial safety evaluation. MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) announced today that the pivotal phase 3 part of the B-MIND clinical study of MOR208 has been opened for enrollment. The randomized, multicenter phase 2/3 study is designed to investigate the efficacy of MOR208 plus bendamustine versus rituximab plus bendamustine in patients with relapsed or refractory diffuse large B cell lymphoma (R/R DLBCL) who are not eligible for high-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT). DLBCL is the most common form of non-Hodgkins lymphoma. MOR208 is an investigational, Fc-enhanced monoclonal antibody directed against CD19 and is being developed for the ...
Full Title A Single-Arm, Open-Label, Multi-Centre, Phase I/II Study Evaluating the Safety and Clinical Activity of AUTO3, A CAR T Cell Treatment Targeting CD19 and CD22 with Anti PD-1 Antibody in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma Purpose In this study, researchers are assessing the best dose of an investigational CAR T-cell therapy when given in combination with pembrolizumab immunotherapy in patients with diffuse large B-cell lymphoma (DLBCL) that has come back or continued to grow despite treatment.
TORCH: A phase II study to determine the safety and efficacy of the dual mTORC inhibitor AZD2014 and to investigate additional toxicities in combination with rituximab in relapsed/refractory Diffuse Large B cell Lymphoma (DLBCL).
One of newest and most exciting approved treatments for cancer is the use of CAR-T therapy. CAR stands for chimeric antigen receptor and T stands for T-cell. Currently both Novartis (NVS) and Gilead (NASDAQ:GILD) have CAR-T therapies approved by the FDA. Axicabtagene (Yescarta) is sold by Gilead and is approved for refractory diffuse large b cell lymphoma(DLBCL). Refractory DLBCL is extremely difficult to treat with a complete response rate of only 7% and median survival of just over 6 months.. Axicabtagene was shown to have a complete response rate of 40%. Tisagenlucleucel (Kymriah) is sold by Novartis and was first approved for treating relapsed B-Cell Acute lymphoblastic leukemia. Both therapies cost north of $300,000 and must be given in a hospital inpatient setting.. A simple explanation of CAR-T therapy is that the patients own T cells are extracted, multiplied, and modified and then re-infused into the patient. These modified T cells then seek out and destroy cancer cells. CAR-T ...
This is a Phase 2, multi-center, open-label, single-arm study of the efficacy and safety of loncastuximab tesirine used as monotherapy in patients with relapsed or refractory DLBCL. The study will enroll approximately 140 patients. Loncastuximab Tesirine is an antibody drug conjugate (ADC) composed of a humanized antibody directed against human cluster of differentiation 19 (CD19), stochastically conjugated via a valine-alanine cleavable, maleimide linker to a pyrrolobenzodiazepine (PBD) dimer cytotoxin. Loncastuximab tesirine has been designed to target and kill CD19-expressing malignant B-cells.. A 2-stage design will be used in this clinical study, with an interim analysis for futility on the first 52 patients. If ≥10 patients respond (CR+PR), the study will proceed to complete full enrollment. Enrollment will continue during the interim analysis; however, further enrollment will be halted if futility is confirmed.. For each patient, the study will include a Screening Period (of up to 28 ...
BACKGROUND: Risk models of chemotherapy-induced (CIN) and febrile neutropenia (FN) have to date focused on determinants measured at the start of chemotherapy. We extended this static approach with a dynamic approach of CIN/FN risk modeling at the start of each cycle.. DESIGN: We applied predictive modeling using multivariate logistic regression to identify determinants of CIN/FN episodes and related hospitalizations and chemotherapy disturbances (CIN/FN consequences) in analyses at the patient (ever during the whole period of chemotherapy) and cycle-level (during a given chemotherapy cycle). Statistical dependence of cycle data being nested under patients was managed using generalized estimation equations. Predictive performance of each model was evaluated using bootstrapped c concordance statistics.. RESULTS: Static patient-level risk models of ever experiencing CIN/FN adverse events and consequences during a planned chemotherapy regimen included predictors related to history, risk ...
RESULTS: Mean age of the patients was 57 years. Mean absolute neutrophil count (ANC) was 436.8/mm3 (range: 0-1000/mm3). In all, 23 of the patients (22.5%) died due to complications related to FN. There were not a statistical difference in therapeutic outcome among tumor types, performance status, sex, depth of neutropenia, or time from emergency department presentationto initiation of antibiotic therapy ...
RESULTS: Mean age of the patients was 57 years. Mean absolute neutrophil count (ANC) was 436.8/mm3 (range: 0-1000/mm3). In all, 23 of the patients (22.5%) died due to complications related to FN. There were not a statistical difference in therapeutic outcome among tumor types, performance status, sex, depth of neutropenia, or time from emergency department presentationto initiation of antibiotic therapy ...
Kaliuresis (/ˌkæljʊərˈiːsɪs/, /ˌkæli-/) or kaluresis (/ˌkæljʊərˈiːsɪs/) is the condition of excreting potassium in the urine. Thiazide diuretics are used to treat patients with heart failure. Their goal is to decrease the amount of salt (sodium chloride) in the body by decreasing the amount that the kidney reabsorbs. This excess sodium in the kidneys that is destined for excretion via urination can cause hyponatremia (low sodium level) and can lead to kaliuresis by increasing sodium-potassium exchange. Natriuresis Harrisons Principles of Internal Medicine, 16th edition Merriam-Webster entry Welling, Paul A. Regulation of Renal Potassium Secretion: Molecular Mechanisms. Seminars in Nephrology. 33 (3): 215-228. doi:10.1016/j.semnephrol.2013.04.002 ...
TY - JOUR. T1 - Incorporating frailty in a multi-state model. T2 - Application to disease natural history modelling of adenoma-carcinoma in the large bowel. AU - Yen, Amy M F. AU - Chen, Tony H H. AU - Duffy, Stephen W.. AU - Chen, Chih Dao. PY - 2010/10. Y1 - 2010/10. N2 - Homogeneous multi-state models of disease progression have been widely used for designing and evaluating cancer screening programs. However, in screening for premalignant conditions of the cervix or large bowel, it is unlikely that all premalignant lesions have the same underlying propensity for progression. Incorporating frailty into multi-state models raises practical difficulties as it precludes the derivation of finite transition probabilities by matrix solution of the Kolmogorov equations. We address this problem by formulating a heterogeneous process as a series of homogeneous processes linked by transitions which are subject to heterogeneity (frailty). Continuous frailty and discrete mover-stayer models were developed. ...
Multi-state models provide a useful framework for estimating the rate of transitions between defined disease states and understanding the influence of covariates on transitions in studies of the disease progression. Statistical analysis of data from studies of disease progression often involves a number of challenges. A particular challenge is that the classification of the disease state may be subject to error. Another common problem is that there are many sources of heterogeneity in the data in which situation the assumption of time-homogeneous for common Markov models is not valid. In addition, it is common for discrete covariates subject to misclassification and the panel data collected from disease progression studies is time-dependence in the covariates. In Chapter 2, the progressive multi-state model with misclassification is developed to simultaneously estimate transition rates and account for potential misclassification. The performance of the maximum likelihood and pairwise likelihood ...
In May 2020, in the middle of SRAS-CoV-2 pandemic, the Chair and Secretary of the IDWP changed. Now, Rafael de la Camara (Madrid, Spain) is the Chair and Dina Averbuch (Jerusalem, Israel) is the new Secretary. We have to thank Dr Jan Styczynski and Dr Malgorzata Mikulska, previous Chair and Secretary, for the excellent work done in the previous four years with a characteristic friendly attitude.. SARS-CoV-2 pandemic has been an important focus for IDWP. At the early stage of the pandemic, the IDWP produced guidelines for the management of SARS-CoV-2 in SCT. The first one was released on March the 1st, and the last update (the 12th version) on December the 2nd, 2020.. As SARS-CoV-2 pandemic has broader implications for SCT and cellular therapies, that goes further from the infectious aspects, a COVID-19 task force has been created to have a holistic approach to the effects of the pandemic. The IDWP is part of this new task force.. In 2021 we are going to launch an annual online certificated ...
This work uses multi-state models of cancer disease progression to explore the misclassification of prostate cancer detected by screening or clinically. It aims to use different models, without or with a time component, to determine the sojourn time for a number of patients within an existing dataset. The outcomes should contribute to tailored approaches to screening for prostate cancer.. ...
Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation and Infectious Complications Subcommittee of the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH), Piñana, J. L., Xhaard, A., Tridello, G., Passweg, J., Kozijn, A., Polverelli, N., Heras, I., Perez, A., Sanz, J., Berghuis, D., Vázquez, L., Suárez-Lledó, M., Itäla-Remes, M., Ozcelik, T., Iturrate Basarán, I., Karakukcu, M., Al Zahrani, M., Choi, G., Cuesta Casas, M. A., Batlle Massana, M., Viviana, A., Blijlevens, N., Ganser, A., Kuskonmaz, B., Labussière-Wallet, H., Shaw, P. J., Arzu Yegin, Z., González-Vicent, M., Rocha, V., Ferster, A., Knelange, N., Navarro, D., Mikulska, M., de la Camara, R. & Styczynski, J., 29-Aug-2020, In : The Journal of Infectious Diseases.. Research output: Contribution to journal › Article › Academic › peer-review ...
His main clinical field is management of patients undergoing allogeneic stem cell transplantation. His research interests are in two major field: diagnosis and management of viral infections, including studies of antiviral drugs in immunocompromised patients and immunizations of the immunocompromised patient. He has held several elected positions in international scientific societies such as chair of the Infectious Diseases Working Party and secretary, European Society for Blood and Marrow Transplantation (EBMT), and council member, vice president, and president, International Immuncompromised Host Society. Prof. Ljungman has authored more than 300 peer-reviewed publications, several book chapters, and is also co-editor of the book Transplant Infections now in its 4th edition. ...
Survival Analysis of Patients with Gastric Cancer Undergoing Surgery at the Iran Cancer Institute: A Method Based on Multi-State Models Gastric cancer;intermediate event;multi-state model;proportional hazards model;survival rate; Background: Gastric cancer is one of the most common causes of cancer deaths all over the world and the most important reason for its high rate of death is its belated diagnosis at advanced stages of the disease. Events occur in patients which are regarded not only as themselves factors affecting patients survival but also which can be affected by other factors. This study was designed and implemented aiming to identify these events and to investigate factors affecting their occurrence. Materials and Methods: Data from 330 patients with gastric cancer undergoing surgery at the Iran Cancer Institute from 1995-1999 were analyzed. The survival time of these patients was determined after surgery and the effects of various factors including demographic, diagnostic and clinical as
In hospital-epidemiology the extended illness-death model, shown in Fig. 1, is a useful tool to study HAIs. The model allows both an etiological exploration of the events infection and in-hospital death and an investigation in terms of absolute risks.. In the extended illness-death model patients start in state 0 which is admission to the hospital. At this time none of the patients is infected. The patients remain in this state until they either leave the hospital without an HAI (state 2 if the discharge is alive, state 3 if the patient dies) or acquire an HAI. The concerned patients then move to state 1. In state 1 the patients remain under observation until discharge alive with an HAI (state 4) or death in the hospital with an HAI (state 5). The model is equivalent to the four-state model where death without and with an HAI are one state (state 3 and 5 are modelled as state 3) as well as discharge without and with an HAI (state 2 and 4 are modelled as state 2). In the four-state extended ...
Andersen, P. K., Borgan, O, Gill, R. D., Keiding, N. Statistical Models Based on Counting Processes. Springer-Verlag, (1993).. Kalbfleisch, J. D., and R. L. Prentice. The Statistical Analysis of Failure Time Data. 2nd ed. New York: Wiley, (2002).. Per Kragh Andersen and Niels Keiding. Multi-state models for event history analysis. Statistical Methods in Medical Research 2002; 11: 91-115.. Per Kragh Andersen, Steen Z Abildstrom, Susanne Rosthøj. Competing risks as a multi-state model. Statistical Methods in Medical Research 2002; 11: 203-215.. ...
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
Please join the RARE Portal to add diseases of interest to your personal profile. By creating a profile, you can receive news, resources and updates related to this disease as well as many other benefits. ...
Key clinical point: Risk factors for chemotherapy-induced febrile neutropenia include corticosteroid use and intravenous antibiotics.Major finding: Corticosteroid use was associated with an increased risk of febrile neutropenia, compared with no corticosteroid use (hazard ratio, 1.53; P less than .01).Study details: This retrospective study included 15,971 patients with non-Hodgkin lymphoma or five solid tumors.
Plasma viscosity estimation is a reflection of changes in plasma proteins within the blood. The values from normal subjects are within a narrowly defined range and change when protein fractions are altered. The major influence on plasma viscosity is exerted by fibrinogen and immunoglobulins. The Viscometer determines viscosity by measuring the resistance of the plasma flow through a capillary under a constant vacuum ...
The absolute risk reduction by prophylaxis in chemotherapy-induced febrile neutropenia (FN) is largest in patients at highest underlying risk. Therefore, reliable predictive models are needed. Here, we develop and validate such a model for risk of FN during chemotherapy cycles 2-6. A prediction score for risk of FN during the first cycle has recently been published1 . Patients with solid cancers initiating first-line chemotherapy in 2010-2016 were included. Cycle-specific risk factors were assessed by Poisson regression using generalised estimating equations and random split-sampling. The derivation cohort included 4,590 patients treated with 15,419 cycles, wherein 326 (2.1%) FN events occurred. Predictors of FN in multivariable analyses were: higher predicted risk of FN in the first cycle, platinum- or taxane-containing therapies, concurrent radiotherapy, treatment in cycle 2 compared to later cycles, previous FN or neutropenia, and not receiving granulocyte colony-stimulating factors. Each ...
Chemotherapy-induced febrile neutropenia (FN) predisposes patients to life-threatening infections and typically requires hospitalization. The goal was to investigate whether a risk assessment tool aligned with national guidelines could help identify patients at risk of FN and reduce FN-related hospitalizations. Beginning in October 2004, oncology nurses applied the new risk assessment tool to all patients initiating chemotherapy or a new regimen. Patients at risk for FN received prophylactic colony-stimulating factor. Charts for 189 patients receiving chemotherapy in fiscal year 2005 (FY05) were compared with charts of 155 patients receiving chemotherapy in FY04, before the tool was implemented. The incidence of FN-related hospitalization declined by 78%, from 9.7% in FY04 to 2.1% in FY05 (P = .003). Total hospital days decreased from 117 to 24. Routine systematic evaluation by oncology nurses improves recognition of patients at risk of FN and substantially reduces FN-related hospitalization.
Snowden JA, Hawkey C, Hind D, Swaby L, Mellor K, Emsley R, Mandefield L, Lee E, Badoglio M, Polge E, Labopin M, Gribben J, Pockley AG, Foulds GA, Lobo A, Travis S, Parkes M, Satsangi J, Papaioannou D, Lindsay JO; Autologous Stem Cell Transplantation In Refractory CD - Low Intensity Therapy Evaluation Study Investigators; European Society for Blood and Marrow Transplantation (EBMT) Autoimmune Diseases Working Party (ADWP ...
Daikeler T, Labopin M, Di Gioia M, Abinun M, Alexander T, Miniati I, Gualandi F, Fassas A, Martin T, Schwarze CP, Wulffraat N, Buch M, Sampol A, Carreras E, Dubois B, Gruhn B, Güngör T, Pohlreich D, Schuerwegh A, Snarski E, Snowden J, Veys P, Fasth A, Lenhoff S, Messina C, Voswinkel J, Badoglio M, Henes J, Launay D, Tyndall A, Gluckman E, Farge D. Secondary autoimmune diseases occurring after HSCT for an autoimmune disease: a retrospective study of the EBMT Autoimmune Disease Working Party. Blood. 2011 Aug 11;118(6):1693- ...
Maximized multi-state compaction and more tolerance in memory state behavior is achieved through a flexible, self-consistent and self-adapting mode of detection, covering a wide dynamic range. For high density multi-state encoding, this approach borders on full analog treatment, dictating analog techniques including A to D type conversion to reconstruct and process the data. In accordance with the teachings of this invention, the memory array is read with high fidelity, not to provide actual final digital data, but rather to provide raw data accurately reflecting the analog storage state, which information is sent to a memory controller for analysis and detection of the actual final digital data.
Maximized multi-state compaction and more tolerance in memory state behavior is achieved through a flexible, self-consistent and self-adapting mode of detection, covering a wide dynamic range. For high density multi-state encoding, this approach borders on full analog treatment, dictating analog techniques including A to D type conversion to reconstruct and process the data. In accordance with the teachings of this invention, the memory array is read with high fidelity, not to provide actual final digital data, but rather to provide raw data accurately reflecting the analog storage state, which information is sent to a memory controller for analysis and detection of the actual final digital data.
Health,... Nursing Home Workers in PA MI IL FL OH MD WI WA Join Forces ... Buyout ...WASHINGTON Oct. 3 -- In an effort to improve...In states where Manor Care has large operations includingPennsylvani...,SEIU,Launches,Multi-State,Grassroots,Campaign,Calling,on,the,Carlyle,Group,to,Put,Care,Above,Profits,in,Buyout,of,Nations,Largest,Nursing,Home,Chain,medicine,medical news today,latest medical news,medical newsletters,current medical news,latest medicine news
Note: An important Network software prerequisite is fully aligned sequence data (the same applies for other phylogenetic software like TCS). Please use the DNA Alignment software for aligning FASTA data and for correctly formatting these into Network binary rdf or Network multi-state rdf files ...
RT @CPearsonAvalere: Multi-state plans (MSPs) will operate in at least 31 state exchanges in 2014. CMS is reviewing 200 plan applications for MSPs.. ...
After introducing the main topic of this paper (the study of purchase incidence and brand choice decisions) we explain basic concepts of hazard models and describe the probability distributions considered in the empirical study presented later. After a review of pure purchase incidence (product category) models as well as integrated models that include brand choice as well, we specify and discuss properties of one-state and multi-state hazard models, respectively. Our conclusions are based on applying hazard models to household scanner data. ...
Dr Piero OlliaroHead of intervention and implementation research at TDRFormer member of the Drugs for Neglected Diseases working groupPiero Olliaro earned his M
We use cookies to ensure that we give you the best experience on our website. If you click Continue well assume that you are happy to receive all cookies and you wont see this message again. Click Find out more for information on how to change your cookie settings ...
The cost of the conference is $65 ($70 after Feb. 7) for the first person from each farm and $55 ($65 after Feb. 7) for each additional person from the farm. This fee includes registration, breaks, trade show, proceedings and Tuesday lunch. The (optional) dinner on Monday evening is $15 ...
Visit For Sample Pages:. https://www.delveinsight.com/sample-request/chemotherapy-induced-febrile-neutropenia-market. Key Benefits of Chemotherapy Induced Febrile Neutropenia Market Report. Chemotherapy Induced Febrile Neutropenia market report provides an in-depth analysis of Chemotherapy Induced Febrile Neutropenia Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.. The Chemotherapy Induced Febrile Neutropenia market report will help in developing business strategies by understanding the Chemotherapy Induced Febrile Neutropenia Market trends & developments, key players and future market competition that will shape and drive the Chemotherapy Induced Febrile Neutropenia market in the upcoming years.. The Chemotherapy Induced Febrile Neutropenia market report covers Chemotherapy Induced Febrile Neutropenia current treatment practices, emerging drugs, market share of the ...
The U.S. Department of Health and Human Services announced today the appointment of 14 members to the new Tick-Borne Disease Working Group.
TY - JOUR. T1 - First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer. T2 - A multicenter, double-blind, placebo-controlled phase III study. AU - Vogel, Charles. AU - Wojtukiewicz, Marek Z.. AU - Carroll, Robert R.. AU - Tjulandin, Sergei A.. AU - Barajas-Figueroa, Luis Javier. AU - Wiens, Brian L.. AU - Neumann, Theresa A.. AU - Schwartzberg, Lee S.. PY - 2005/2/20. Y1 - 2005/2/20. N2 - Purpose: We evaluated the efficacy of pegfilgrastim to reduce the incidence of febrile neutropenia associated with docetaxel in breast cancer patients. Patients and Methods: Patients were randomly assigned to either placebo or pegfilgrastim 6 mg subcutaneously on day 2 of each 21-day chemotherapy cycle of 100 mg/m2 docetaxel. The primary end point was the percentage of patients developing febrile neutropenia (defined as body temperature ≥ 38.2°C and neutrophil count , 0.5 × 109/L on the same day of the fever or the day after). Secondary end points were ...
Ronald Gangnon is Professor of Biostatistics with a joint appointment in the Department of Population Health Sciences and the Department of Biostatistics & Medical Informatics. He also has an affiliate appointment in the Department of Statistics. Dr. Gangnon earned his BA degree in Mathematics and Economics at the University of Minnesota-Duluth (1992) and his MS (Statistics, 1994) and PhD (Statistics with emphasis in Biostatistics, 1998) from the University of Wisconsin-Madison. Dr. Gangnons research interests are in the development and application of statistical methods in clinical and epidemiologic research. Areas of methodologic interest include spatial epidemiology, with emphasis on detection and modeling of spatial and spatio-temporal clusters, syndromic surveillance, age-period-cohort modeling, multi-state models and ranking. Dr. Gangnon serves as Director of the Biostatistics Core for the Childhood Origins of ASThma (COAST) project, a prospective birth cohort study of early childhood ...
Multi-State Insurance has the capacity to cooperate with several financially stable and renowned insurance companies, therefore providing them with the
Downloadable! multistate provides a set of commands for multi-state survival analysis. This includes msset, a data preparation tool which converts a dataset from wide (one observation per subject, multiple time and status variables) to long (one observation for each transition of which a subject is at risk), and predictms, which calculates transition probabilities, and many other useful measures of absolute risk, following the fit of a model using streg, or stpm2. predictms allows different families of models to be specified for each transition. All quantities are calculated through simulation, including confidence intervals. Differences and ratios across covariate patterns can be calculated.
Beth Carrison, co-founder of Tick-Borne Conditions United, delivered these remarks to the Tick-Borne Disease Working Group on July 8.
[Febrile neutropenia is one of the most feared complications of anti-tumor therapy. It can either herald potentially fatal infection or contribute to suboptimal dose-intensity of cancer treatment. Optimal management of affected patients is based upon a multi-disciplinary approach dependent on several factors. Knowledge on institutional epidemiology and predefi ned management strategies improve quality and outcome of anti-infective therapy. In an era of more and more resistant pathogens and erosion of the antimicrobial armamentarium clinicians taking care of cancer patients carry increased responsibility in their professional activity. Here questions of practical importance related to prevention and therapy of neutropenic infections are outlined.]
Amgen Inc. - Barcelona, Spain, June 14, 2010 (ots/PRNewswire) - Data presented at the 15th European Hematology Association (EHA) congress in Barcelona, highlights the impact of febrile neutropenia (FN) on chemotherapy delivery in non-Hodgkin ...
Febrile Neutropenia. On-line free medical diagnosis assistant. Ranked list of possible diseases from either several symptoms or a full patient history. A similarity measure between symptoms and diseases is provided.
Learn about a GCS-F indicated to help reduce the incidence of infection manifested by febrile neutropenia (FN) in patients at risk of FN.
CLEVELAND - Twelve defendants were indicted Tuesday in a major drug trafficking conspiracy in which large shipments of cocaine were flown by private chartered airplanes from Texas to Cleveland....
After undergoing screening procedures to confirm that you are eligible to participate in the research study you will be admitted to the hospital. You will likely receive the majority of treatment on an inpatient basis. You will remain in the hospital for at least Days 4-8 and will be discharged at the discretion of your study doctor. It is likely that you will be hospitalized for several weeks due to the risk of infection after chemotherapy.. Since we are looking for the highest dose of the study drug that can be administered safely without severe or unmanageable side effects in participants that have relapsed or refractory AML, not everyone who participates in this research study will receive the same dose of the study drug. The dose you get will depend on the number of participants who have been enrolled in the study before you and how well they have tolerated their doses.. If you take part in this study you will be given a study drug-dosing calendar. There is only one cycle of treatment, ...
Buoyed by cheering crowds and bolstered by more than $1.3 million a day in TV ads, candidates made their last pleas for votes before the multi-state contests begin.
When can I submit an application?. Deadlines for multi-state partners to submit applications to Participating States, and for Participating States to submit applications to AMS will be announced in the Request for Applications.. What are the application requirements?. You can find the requirements for preparing an application in the most recent Request for Applications.. ...
With COVID-19 case counts on the rise, its important to know what to expect from our transportation providers this winter. Overall, long distance and multi-state moves are more challenging due to a lack of return transportation availability.  ACERTUS and […]
Neulasta is approved as a treatment for patients undergoing chemotherapy, to decrease the incidence of infection by febrile neutropenia. It is administered...
Remedial treatments to deal with chemotherapy-induced toxicities is through injection of granulocyte colony-stimulating factor ... specifically with observed febrile neutropenia, neurotoxicity, ototoxicity, and nephrotoxicity. ... For systemic chemotherapy (issued orally or intravenously), the regimen is standardised in every FIGO staging to comprise ... With a recurrence up to 15-25% for early-stage patients, adjuvant chemotherapy needs to couple with surgical resection of tumor ...
Fermented wheat germ extract reduces chemotherapy-induced febrile neutropenia in pediatric cancer patients. J Pediatric Hematol ... Fermented wheat germ extract induces apoptosis and downregulation of major histocompatibility complex class I proteins in tumor ...
... concentrations are early predictors of septic shock development in patients with post chemotherapy febrile neutropenia". BMC ... This quiescence or slow cell cycling of HSCs induced by Tie-2/Ang-1 signaling contributes to the maintenance of long-term ... It has been also implicated to play role in hepatocellular and endometrial carcinoma-induced angiogenesis. Experiments using ... 2013). "Kaposi's sarcoma-associated herpesvirus induces rapid release of angiopoietin-2 from endothelial cells". J Virol. 87 ( ...
Use of anthracyclines has also been shown to be significantly associated with cycle 1 severe or febrile neutropenia. Other ... Angsutararux P, Luanpitpong S, Issaragrisil S (2015). "Chemotherapy-Induced Cardiotoxicity: Overview of the Roles of Oxidative ... It was first recognised to be related to the oxidative stress induced by anthracyclines. A more recent explanation has emerged ... Cytotoxicity is primarily due to inhibition of topoisomerase II after the enzyme induces a break in DNA, preventing religation ...
Haematological adverse effects include neutropenia (95.5%), anaemia (90.4%), febrile neutropenia (11.0%) and thrombocytopenia ( ... As with all chemotherapy, adverse effects are common, and many side effects have been documented. Because docetaxel is a cell- ... When used with anticonvulsants, which induce CYP3A4, an increased dose of docetaxel may be required. Pre-treatment with ... It may be used by itself or along with other chemotherapy medication. It is given by slow injection into a vein. Common side ...
Causes of neutropenia include chemotherapy and bone marrow transplantation. Filgrastim is also used to increase the number of ... Shortly after it was introduced, analyses of whether filgrastim is a cost-effective way of preventing febrile neutropenia ... Moore DC, Pellegrino AE (September 2017). "Pegfilgrastim-Induced Bone Pain: A Review on Incidence, Risk Factors, and Evidence- ... Exploration of Risk Factors for Febrile Neutropenia". Supportive Cancer Therapy. 3 (1): 36-46. doi:10.3816/SCT.2005.n.023. PMID ...
... reduction in the duration of neutropenia and the incidence of febrile neutropenia in adults treated with cytotoxic chemotherapy ... "Lipegfilgrastim in the management of chemotherapy-induced neutropenia of cancer patients". Biologics. 10: 1-8. doi:10.2147/BTT. ... is a medication used to reduce the duration of neutropenia and the incidence of febrile neutropenia in adults. It is given by ... treatment comparison of lipegfilgrastim with pegfilgrastim and filgrastim for the reduction of chemotherapy-induced neutropenia ...
Common adverse effects with cabazitaxel include neutropenia (including febrile neutropenia) and GIT side effects appeared ... September 2011). "Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in ... However, C20 and C25 did not demonstrate superiority for OS versus D75 in patients with chemotherapy-naïve mCRPC. Cabazitaxel ... Cabazitaxel was associated with more grade 3-4 neutropenia (81.7%) than mitoxantrone (58%). ...
... is frequently given in the treatment of febrile neutropenia. This condition frequently occurs in patients with ... Margolin, L (2004). "Impaired rehabilitation secondary to muscle weakness induced by meropenem". Clinical Drug Investigation. ... Antimicrobial Agents and Chemotherapy. 54 (7): 2974-8. doi:10.1128/AAC.01582-09. PMC 2897321. PMID 20479205. Yu Z, Pang X, Wu X ... Journal of Antimicrobial Chemotherapy. 72 (3): 782-790. doi:10.1093/jac/dkw476. PMC 5890718. PMID 27999041. "Hefny Pharma Group ...
A neutropenic fever, also called febrile neutropenia, is a fever in the absence of normal immune system function.[citation ... it is sometimes difficult to determine a febrile stage.[citation needed] Fever can also be behaviorally induced by ... This kind of fever is more commonly seen in people receiving immune-suppressing chemotherapy than in apparently healthy people ... Rarely a fever may trigger a febrile seizure, with this being more common in young children. Fevers do not typically go higher ...
... has been shown in three clinical trials to significantly reduce the occurrence of chemotherapy-induced neutropenia and the ... when combined with profound neutropenia (febrile neutropenia), is considered a medical emergency and requires broad spectrum ... neutropenia, cyclic neutropenia, autoimmune neutropenia, and congenital neutropenia.[medical citation needed] Neutropenia that ... drug-induced neutropenia). Additionally, acute neutropenia can be commonly seen from people recovering from a viral infection ...
1997). Febrile Neutropenia. Berlin, Heidelberg: Springer Berlin Heidelberg. doi:10.1007/978-3-642-60443-0. ISBN 978-3-540-61230 ... Allergic reactions can be induced from the side chains of β-lactam antibiotics such as amoxicillin, or antibodies surrounding ... Piperacillin/tazobactam Nosocomial Pneumonia Study Group". The Journal of Antimicrobial Chemotherapy. 43 (3): 389-97. doi: ... A dosage of 90mg/kg every 6 hours is suggested for infants and children diagnosed with neutropenia. Common side effects ...
... has been studied as an alternative to vancomycin in the treatment of febrile neutropenia in cancer patients when Gram ... Long-term use of linezolid has also been associated with chemotherapy-induced peripheral neuropathy, a progressive and enduring ... del Pino BM (23 February 2010). "Chemotherapy-induced Peripheral Neuropathy". NCI Cancer Bulletin. 7 (4): 6. Archived from the ... Chemotherapy drugs associated with CIPN include thalidomide, the epothilones such as ixabepilone, the vinca alkaloids ...
... characterized by neutropenia and fever) is similar to the one used for other febrile neutropenic patients. However, important ... Ingestion of radioactive materials caused many radiation-induced cancers in the 1930s, but no one was exposed to high enough ... Journal of Antimicrobial Chemotherapy. 33 (1): 63-74. doi:10.1093/jac/33.1.63. ISSN 1460-2091. PMID 8157575. Patchen ML, Brook ... Individuals that develop neutropenia after exposure to radiation are also susceptible to irradiation damage in other tissues, ...
Febrile neutropenia (fever due to decrease in white blood cells) occurs in 10 to 14% and death due to toxicity in about 3-4%. ... cisplatin-based chemotherapy Metastatic disease but unfit for cisplatin-based chemotherapy: carboplatin-based chemotherapy ... Schistosoma eggs induces a chronic inflammatory state in the bladder wall resulting in tissue fibrosis. Higher levels of N- ... Role of adjuvant chemotherapy (chemotherapy after main treatment) is limited to people with high grade tumours (pT3/T4and/or N+ ...
Chemotherapy-induced hyperpigmentation Drug-induced acne Drug-induced angioedema Drug-related gingival hyperplasia Drug-induced ... Cyclic neutropenia Desquamative gingivitis Drug-induced ulcer of the lip Epidermization of the lip Epulis Epulis fissuratum ( ... Wallach D, Vignon-Pennamen MD (2006). "From acute febrile neutrophilic dermatosis to neutrophilic disease: forty years of ... induced Hair dye-induced Hair lotion-induced Hair spray-induced Hair straightener-induced Hair tonic-induced Houseplant-induced ...
... and a significant reduction in febrile neutropenia. These findings could have major implications for treating patients with ... Anthracyclines are important chemotherapy agents. However, their use is associated with irreversible and cumulative heart ... Pixantrone inhibits antigen specific and mitogen induced lymphomononuclear cell proliferation, as well as IFN-gamma production ... randomized clinical trial studied pixantrone to see how well it works compared to other chemotherapy drugs in treating patients ...
Febrile neutropenia, Friedreich's ataxia (T), Gastrointestinal bleeding, Gastroesophageal reflux disease, Gaucher's disease, ... Heparin-induced thrombocytopenia (T, good article since 1 January 2010), Hereditary hemorrhagic telangiectasia (T, good article ... Chemotherapy, Colchicine, Danazol (T), Dantrolene (T), Demeclocycline, Desiccated thyroid extract, Dexamethasone, Doxapram, ... Coeliac disease (T / featured since 26 March 2007), Colorectal cancer, Constipation, Contrast-induced nephropathy (T), ...
Refractory chemotherapy-induced nausea and vomiting; anorexia; neuropathic pain.. Dizziness, euphoria, paranoia, somnolence, ... For systemic use haematological side effects such as aplastic anaemia; agranulocytosis; leucopenia; neutropenia; etc. ... "Evidence on the use of paracetamol in febrile children". Bulletin of the World Health Organization. 81 (5): 367-72. PMC ... Pain; anaesthesia supplement; opioid-induced pruritus.. As per codeine. Respiratory depression is subject to ceiling effect. ...
Refractory chemotherapy-induced nausea and vomiting; anorexia; neuropathic pain.. Dizziness, euphoria, paranoia, somnolence, ... For systemic use haematological side effects such as aplastic anaemia; agranulocytosis; leucopenia; neutropenia; etc. ... "Evidence on the use of paracetamol in febrile children". Bulletin of the World Health Organization. 81 (5): 367-72. PMC ... Opioid-induced hyperalgesia is when exposure to opioids increases the sensation of pain (hyperalgesia) and can even make non- ...
Refractory chemotherapy-induced nausea and vomiting; anorexia; neuropathic pain.. Dizziness, euphoria, paranoia, somnolence, ... For systemic use haematological side effects such as aplastic anaemia; agranulocytosis; leucopenia; neutropenia; etc. ... "Evidence on the use of paracetamol in febrile children". Bulletin of the World Health Organization. 81 (5): 367-72. PMC ... Bannister K (June 2015). "Opioid-induced hyperalgesia: where are we now?". Current Opinion in Supportive and Palliative Care. 9 ...
Refractory chemotherapy-induced nausea and vomiting; anorexia; neuropathic pain.. Dizziness, euphoria, paranoia, somnolence, ... For systemic use haematological side effects such as aplastic anaemia; agranulocytosis; leucopenia; neutropenia; etc. ... "Evidence on the use of paracetamol in febrile children". Bulletin of the World Health Organization. 81 (5): 367-72. PMC ... Pain; anaesthesia supplement; opioid-induced pruritus.. As per codeine. Respiratory depression is subject to ceiling effect. ...
History of chronic comorbidity and risk of chemotherapy induced febrile neutropenia in cancer patients not receiving G-CSF ... Chronic comorbid conditions associated with risk of febrile neutropenia in breast cancer patients treated with chemotherapy. ...
... lives by helping them avoid life-threatening chemotherapy-related events such as severe neutropenia and febrile neutropenia. ... ALRN-6924 has demonstrated a protective effect against chemotherapy-induced bone marrow toxicities, including neutropenia, ... lives by helping them avoid life-threatening chemotherapy-related events such as severe neutropenia and febrile neutropenia. ... Grade 4 neutropenia and febrile neutropenia, as well as duration of Grade 4 neutropenia. An additional primary endpoint is the ...
Beyond classical chemotherapy, treatment can involve multiple classes of therapies, such as immune check- point inhibitors. ... Clinical Guide to Antineoplastic Therapy: A Chemotherapy Handbook (Fourth Edition) The landscape of cancer treatment is ... cancer regardless of absolute neutrophil count and without G-CSF does not increase chemotherapy-induced febrile neutropenia, ... How does chemotherapy work. Chemotherapy works by stopping or slowing the growth of cancer cells, which grow and divide quickly ...
... undertaking than a systematic review of colony-stimulating factors in preventing chemotherapy-induced febrile neutropenia in ...
Empiric use of daptomycin for febrile neutropenia in hematopoietic stem cell transplant patients colonized with vancomycin- ... Fleer, R. Grauer, D. Henry, D. Rockey, M. & Hosmer, K. (2018). Medication interactions with oral chemotherapy agents: a focus ... Burke, E. Grauer, D. Henry, D. Neupane, P. & Rockey, M. . (12/31/2016). Assessment of cetuximab-induced infusion reactions and ... Empiric use of daptomycin for febrile neutropenia in hematopoietic stem cell transplant patients colonized with vancomycin- ...
Preventing Chemotherapy-Induced Infertility in Female Patients. By Shiela McCollam, PharmD, BCPS; Colleen Shipman, PharmD, MPH ... of Intravenous Fluid Shortages on the Time to Antibiotic Administration in the Treatment of Patients with Febrile Neutropenia ... Chemotherapy Administration Sequencing: An Update on the Current Literature. Alanna D. Lehman, PharmD, BCOP; Anna Howard, ... Use of Nanoparticle Albumin-Bound Paclitaxel in Patients with Breast Cancer and Paclitaxel-Induced Pneumonitis: Single-Center ...
Clinical impact of cycling the administration of antibiotics for febrile neutropenia in Japanese patients with hematological ... R-Spondin1 expands Paneth cells and prevents dysbiosis induced by graft-versus-host disease. -. Journal of experimental ... Cytogenetically Unrelated Clones in Acute Myeloid Leukemia Showing Different Responses to Chemotherapy. -. Case reports in ... A novel heterozygous ITGB3 p.T720del inducing spontaneous activation of integrin αIIbβ3 in autosomal dominant ...
Naloxegol for treating opioid‑induced constipation - NICE TAG TA345 * Methylnaltrexone bromide for treating opioid-induced ... Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy- NICE TAG TA428. 1.1Pembrolizumab is ... 4.8.3 Febrile convulsions * 4.9 Drugs used in parkinsonism and related disorders * 4.9.1 Dopaminergic drugs used in Parkinsons ... 9.1.6 Drugs used in neutropenia * 9.1.7 Drugs used to mobilise stem cells ...
Naloxegol for treating opioid‑induced constipation - NICE TAG TA345 * Methylnaltrexone bromide for treating opioid-induced ... Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy - NICE TAG TA374 ... 4.8.3 Febrile convulsions * 4.9 Drugs used in parkinsonism and related disorders * 4.9.1 Dopaminergic drugs used in Parkinsons ... 9.1.6 Drugs used in neutropenia * 9.1.7 Drugs used to mobilise stem cells ...
Naloxegol for treating opioid‑induced constipation - NICE TAG TA345 * Methylnaltrexone bromide for treating opioid-induced ... Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy - NICE TAG TA374 ... 4.8.3 Febrile convulsions * 4.9 Drugs used in parkinsonism and related disorders * 4.9.1 Dopaminergic drugs used in Parkinsons ... 9.1.6 Drugs used in neutropenia * 9.1.7 Drugs used to mobilise stem cells ...
Naloxegol for treating opioid‑induced constipation - NICE TAG TA345 * Methylnaltrexone bromide for treating opioid-induced ... Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy - NICE TAG TA374 ... 4.8.3 Febrile convulsions * 4.9 Drugs used in parkinsonism and related disorders * 4.9.1 Dopaminergic drugs used in Parkinsons ... 9.1.6 Drugs used in neutropenia * 9.1.7 Drugs used to mobilise stem cells ...
Naloxegol for treating opioid‑induced constipation - NICE TAG TA345 * Methylnaltrexone bromide for treating opioid-induced ... Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy - NICE TAG TA374 ... 4.8.3 Febrile convulsions * 4.9 Drugs used in parkinsonism and related disorders * 4.9.1 Dopaminergic drugs used in Parkinsons ... 9.1.6 Drugs used in neutropenia * 9.1.7 Drugs used to mobilise stem cells ...
  • ALRN ), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients, announced today that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, is scheduled to participate in a fireside chat at the William Blair Biotech Focus Conference 2021 at 3:00 p.m. (biopharmcatalyst.com)
  • Aileron is a clinical stage chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients. (biopharmcatalyst.com)
  • By reducing or eliminating multiple chemotherapy-induced side effects, ALRN-6924 may improve patients' quality of life by enabling them to better tolerate chemotherapy. (biopharmcatalyst.com)
  • It also may save patients' lives by helping them avoid life-threatening chemotherapy-related events such as severe neutropenia and febrile neutropenia. (biopharmcatalyst.com)
  • Our vision is to bring chemoprotection to patients with p53-mutated cancers, which represent approximately 50% of cancer patients, regardless of type of cancer or chemotherapy. (biopharmcatalyst.com)
  • Thus, a systematic review on the use of colony-stimulating factors in patients with hematologic malignancies will be a far greater undertaking than a systematic review of colony-stimulating factors in preventing chemotherapy-induced febrile neutropenia in children with acute lymphoblastic leukemia. (nichi.com)
  • Medication interactions with oral chemotherapy agents: a focus on the BCR-ABL tyrosine kinase inhibitors in patients with chronic myeloid leukemia. (ku.edu)
  • Free Book Cancer Chemotherapy In Clinical Practice # Uploaded By Barbara Cartland, practical aspects covering dosing and drug delivery together with an extensive discussion of possible side effects and their management chemotherapy in the management of cancer explaining the place of drug treatment and the outcomes that can be. (naba-hairstreak.com)
  • Intended as an introductory text for junior doctors, nurses and medical students, Cancer Chemotherapy in Clinical Practice is divided into three sections: The Theoretical Basis of Cancer Chemotherapy - following a historical introduction the different treatment modalities are explained in. (naba-hairstreak.com)
  • Clinical Interpretations and Practice of Cancer Chemotherapy limits its approach to the drugrelated aspects of the treatment of cancer. (naba-hairstreak.com)
  • This book is intended as a basic overview of the drug treatment of cancer for junior doctors and specialist nurses who come into contact with people having chemotherapy as part of their day-- day work. (naba-hairstreak.com)
  • students cancer chemotherapy in clinical practice is divided into three sections the theoretical basis of cancer chemotherapy following a historical introduction the different treatment modalities are explained in the context of basic tumor biology the first use of the word chemotherapy is credited to paul ehrlich who used it to. (naba-hairstreak.com)
  • cancer chemotherapy in clinical practice Posted By Patricia Cornwell Public Library TEXT ID e Online PDF Ebook Epub Library introduction the different treatment modalities are explained in the context of basic tumor biology the last decade has seen many dramatic changes in cancer chemotherapy. (naba-hairstreak.com)
  • This precision medicine-driven approach is designed to selectively protect multiple healthy cell types throughout the body from chemotherapy while ensuring we do not protect cancer cells. (biopharmcatalyst.com)
  • As a result, healthy cells are spared from chemotherapeutic destruction while chemotherapy continues to kill cancer cells. (biopharmcatalyst.com)
  • 4 edition of Clinical interpretation and practice of cancer chemotherapy found in the catalog. (naba-hairstreak.com)
  • Cancer -- Chemotherapy. (naba-hairstreak.com)
  • Cancer Chemotherapy: Principles and Practice. (naba-hairstreak.com)
  • cancer chemotherapy in clinical practice Posted By Richard Scarry Library TEXT ID c2 Online PDF Ebook Epub Library fields of cytotoxic and hormonal therapy this book summarises the whole range of systemic cancer Clinical interpretation and practice of cancer chemotherapy book. (naba-hairstreak.com)
  • cancer chemotherapy in clinical practice Posted By Stephen King Media Publishing TEXT ID e Online PDF Ebook Epub Library practice getting the books cancer chemotherapy in clinical practice now is not type of challenging means you could not unaided going following books buildup or library or. (naba-hairstreak.com)
  • cancer chemotherapy in clinical practice Posted By Stan and Jan books to browse the normal book fiction history novel scientific research as capably as various supplementary sorts of books cancer chemotherapy in clinical practice sep 11 posted cancer chemotherapy in clinical practice is divided into three sections the. (naba-hairstreak.com)

No images available that match "chemotherapy induced febrile neutropenia"